Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

Amivantamab-vmjw

Amivantamab-vmjw
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Rybrevant INJECTION, INTRAVENOUS 50 mg/mL      
VIEW MORE Antineoplastic Agents
CLASS
100000
Comments:

Restricted to use by Oncology in the outpatient setting. Each case will be evaluated for reimbursement or specialty benefits prior to use.

Reviewed: July 2022 (Rybrevant)

Last updated: Jul. 28, 2022






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved